Cyclooxygenase-2 (COX-2) is frequently overexpressed in human cancers and contributes to the malignant phenotype. Our data indicate unphosphorylated signal transducers and activators of transcription 6 (STAT6) may transcriptionally upregulate COX-2 expression and protect against apoptosis in NSCLC cells. In A427 and H2122, NSCLC cell lines that constitutively express COX-2, only unphosphorylated STAT6 was detectable by western blot, thus, all of the following STAT6-dependent effects are attributed to the unphosphorylated protein.
Introduction
Cyclooxygenase (COX, also referred to prostaglandin G/H synthase) is often the rate-limiting enzyme for the production of prostaglandins and thromboxanes from free arachidonic acid. Two forms of COX have been described: a constitutively expressed enzyme, COX-1, present in most cells and tissues, and an inducible isoenzyme, COX-2, expressed in response to cytokines, growth factors and other stimuli (Herschman, 1999) . COX-2 has been found to be constitutively elevated in lung cancer and may be involved in tumorigenesis by regulation of apoptosis, angiogenesis, tumor invasion and tumor immunity (Sheng et al., 1998; Stolina et al., 2000; Dohadwala et al., 2002; Pold et al., 2004) .
Signal transducers and activators of transcription (STAT) are a family of transcription factors activated in response to cytokines and peptide growth factors. Currently, there are seven members in this family, including STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. Each of these is activated by specific stimuli. STAT6 was originally identified as a gamma-activated sequence binding protein in extracts derived from interleukin (IL)-4-treated cell lines (Kotanides and Reich, 1993; Hou et al., 1994; Schindler et al., 1994) . Accordingly, IL-4 can specifically induce tyrosine phosphorylation of STAT6.
The initial model for STAT signaling involves a specific cytokine binding to its cognate receptor and promoting the transphosphorylation of receptor associated tyrosine kinases from the Janus-activated kinase family (JAK). Activated JAK kinases in turn phosphorylate-specific tyrosine motifs found in receptor domains, which then recruit the specific monomeric STATs to the receptor complex. Consequently, the STATs are phosphorylated at a single tyrosine site, become activated and dimerize. Dimerization is followed by translocation into the nucleus and binding to the responding DNA (Leonard and O'Shea, 1998) . However, recent studies have suggested that STAT signaling is more complicated than originally thought, and unphosphorylated STATs are also able to regulate gene expression. For example, unphosphorylated STAT1 and interferon regulatory factor-1 can form a complex and support transcription of the LMP2 gene (Chatterjee-Kishore et al., 2000) . Similarly, microarray analyses comparing global gene expression in cells that overexpress wild-type STAT3 or phosphorylation-deficient mutant indicate that a subset of genes are regulated by unphosphorylated STAT3, including well-known oncogenes such as MRAS and MET . Here, we report that unphosphorylated STAT6 is present in the nucleus and may facilitate constitutive COX-2 expression in NSCLC cells via binding to the COX-2 promoter in association with p300.
Results
Inhibition of unphosphorylated STAT6 expression leads to decreased constitutive COX-2 expression The phosphorylation status of STAT6 in A427 and H2122 cells was determined by Western blot. STAT6 was constitutively unphosphorylated in these cells and phosphorylation of STAT6 could only be detected following exposure to IL-4 (Supplementary data). To determine the role of STAT6 in regulating constitutive COX-2 expression, cells were transiently transfected with a small-interfering RNA (siRNA) targeting the exon 4 sequence of the STAT6 gene (ID#4501). STAT6 expression was suppressed by the siRNA in both cell lines, and the suppression did not occur with control siRNA containing a random sequence. As a result, decreased STAT6 levels led to decreased COX-2 protein levels in both cell lines (Figure 1 ). To exclude the possibility that the results were due to nonspecific effects of this particular STAT6 siRNA, another siRNA targeting the exon 22 sequence of the STAT6 gene (ID#4689) was utilized. The suppression of STAT6 mediated by this siRNA also decreased COX-2 expression (data not shown). Thus, these findings indicate that unphosphorylated STAT6 may be implicated in regulating constitutive COX-2 expression in NSCLC cells.
Constitutive COX-2 expression is decreased in STAT6 dominant-negative (STAT6 DN) cell lines and increased in tyrosine-mutant STAT6 (STAT6Y641W) cell lines To further investigate the role of STAT6 in regulating constitutive COX-2 expression, a deleted form of STAT6 lacking the C-terminal 186 amino acids (aa) (from 662-847, MW 75 kDa) that has been shown to act dominant-negatively (STAT6 DN) was constructed and stable cell lines were established (Mikita et al., 1996) . Western blot analysis showed that the COX-2 protein levels were significantly decreased in the STAT6 DN cells compared to the parental or vector-containing cells (Figure 2a ). Although phosphorylated STAT6 was not detected in the cells, we considered the possibility that very low levels of phosphorylated STAT6 were present below the level of detection by Western blot. To exclude this possibility, we constructed a phosphorylationdeficient STAT6 mutant in which the potential phosphorylated tyrosine at position 641 was mutated to a tryptophan (STAT6Y641W). COX-2 protein levels were significantly increased in STAT6Y641W cells compared to parental or vector-containing cells (Figure 2b ). Because COX-2 is often the rate-limiting enzyme in the production of prostaglandin E 2 (PGE 2 ) which mediates many tumorigenic effects (Sheng et al., 1998; Stolina et al., 2000; Dohadwala et al., 2002; Pold et al., 2004) , we determined the PGE 2 concentrations in the supernatants of STAT6Y641W cell lines. Compared to the vector-containing cells, PGE 2 production was increased 149 and 137% in A427 and H2122 STA-T6Y641W cells, respectively (Figure 3 ).
STAT6 is localized in the nucleus
Previously, unphosphorylated STAT family members have been assumed to be present in the cytoplasm. However, recent studies suggest unphosphorylated STAT1, 3 and 5 may also localize to the nucleus Unphosphorylated STAT6 increases COX-2 in NSCLC X Cui et al Zeng et al., 2002; Bhattacharya and Schindler, 2003) . If unphosphorylated STAT6 can regulate gene expression, it may exist in the nucleus as well. To test this hypothesis, immunofluorescent staining was performed using a STAT6 monoclonal antibody that recognizes 650-765 aa of unphosphorylated STAT6. Unphosphorylated STAT6 was detected in the nucleus ( Figure 4 ).
Unphosphorylated STAT6 and p300 bind the COX-2 promoter and may facilitate COX-2 expression via their interaction As a transcription factor, STAT6 usually recognizes a consensus-binding site (TTCTGTTGAA) to induce the transcription of the responding gene. We found the same site located at À713 to À722 bp of the COX-2 promoter. To investigate whether unphosphorylated STAT6 binds to this site, chromatin immunoprecipitation (ChIP) assays using anti-STAT6 antibody were performed and demonstrated that unphosphorylated STAT6 bound to this consensus site ( Figure 5a ). It has been reported previously that IL-4-induced phosphorylated STAT6 interacts with p300 to mediate gene transcription (McDonald and Reich, 1999) . To investigate whether p300 is involved in a similar manner for unphosphorylated STAT6, another ChIP assay using anti-p300 antibody was performed and demonstrated that p300 also bound to the same site as unphosphorylated STAT6 (Figure 5a ). To investigate whether p300 and unphosphorylated STAT6 bind to each other, indicates the presence of antibodies for STAT6 or p300 ( þ ) or their IgG control antibodies (-). Each sample DNA was amplified by PCR with primers to the STAT6 binding site or negative control primers to ensure equal amounts of DNA were utilized in the PCR reaction. (b) Co-immunoprecipitation assay of STAT6Y641W and p300. 293 cells were transfected with STAT6Y641W and/or p300. Cell lysates were directly subjected to Western blot to assess the expression of STAT6 and p300. Cell lysates were also immunoprecipitated with p300 antibody and then subjected to Western blotting. The membrane was probed with STAT6 antibody.
Unphosphorylated STAT6 increases COX-2 in NSCLC X Cui et al plasmids expressing STAT6Y641W or p300 were transfected either alone or together into 293 cells, which do not express STAT6 endogenously. Transfection of STAT6Y641W led to its co-precipitation with cotransfected p300 or endogenous p300, demonstrating that unphosphorylated STAT6 and p300 could directly interact with each other (Figure 5b ). Thus, unphosphorylated STAT6 binds to the COX-2 promoter in association with p300 to regulate COX-2 gene transcription.
Unphosphorylated STAT6 increases COX-2 promoter activities and binds to the COX-2 promoter sequence in vitro To further determine whether unphosphorylated STAT6 regulates COX-2 transcription, COX-2 promoter constructs containing or lacking the potential STAT6 binding site (À1432/ þ 59 bp and À327/ þ 59 bp, respectively) were co-transfected with the STAT6Y641W construct into 293 cells. COX-2 promoter activity was increased to 158% with the presence of the STAT6 binding site, whereas it remained unchanged with the absence of the STAT6 binding site (Figure 6a ), suggesting the STAT6 binding site in the COX-2 promoter is essential for the function of unphosphorylated STAT6.
To further prove the specificity of the binding of STAT6 to the COX-2 promoter sequence, electrophoretic mobility shift assays (EMSA) were performed utilizing a 30 bp oligo from the COX-2 promoter sequence encompassing the STAT6 binding site as a probe. Binding to the COX-2 promoter sequence could be specifically inhibited by excess amount of cold wild-type probes, but not by STAT6 binding site-mutant probes (Figure 6b and c).
Unphosphorylated STAT6 affects cell sensitivity to apoptosis
The regulation of COX-2 by unphosphorylated STAT6 suggests that it may play a role in controlling COX-2-dependent modulation of the malignant phenotype. To explore the physiological significance of unphosphorylated STAT6, the sensitivity of apoptosis of the STAT6 DN cells and STAT6Y641W cells was investigated. Cisplatin, a commonly used chemotherapeutic reagent in lung cancer treatment (Wang and Lippard, 2005; Chattopadhyay et al., 2006) , was utilized to treat the cells. The induction of apoptosis was determined by poly ADP-ribose polymerase (PARP) cleavage through Western analysis. STAT6 DN cells were found to be more sensitive to cisplatin in both cell lines (Figure 7) . In A427 cells, PARP cleavage was detected in STAT6 DN cells at 50 mM of cisplatin compared to control cells at 100 mM, whereas in H2122, it was 250 mM versus 500 mM.
In contrast, STAT6Y641W cells are more resistant to apoptosis (Figure 7) . In A427 STAT6Y641W cells, PARP cleavage was detected at 200 mM of cisplatin, whereas it was detected at 50 mM in control cells (the dimethylsulfoxide solution appears to slightly induce apoptosis). In H2122 cells, the PARP cleavage was clearly detected at 500 mM in control cells whereas it was barely detectable in STAT6Y641W cells at the same concentration. These findings suggest that unphosphorylated STAT6 protects NSCLC cells from apoptosis.
Discussion
In this study, using three independent approaches, we demonstrate that unphosphorylated STAT6 contributes to COX-2 expression in two well-studied NSCLC cell lines. Knockdown of endogenous STAT6 with siRNA or expression of a dominant-negative STAT6 led to a significant decrease in constitutive COX-2 expression. In a third approach, we overexpressed a phosphorylationdeficient mutant of STAT6 and showed an increase in COX-2 expression, confirming that unphosphorylated STAT6 can upregulate COX-2 expression in NSCLC.
To investigate the mechanism of the regulation of COX-2 expression by unphosphorylated STAT6, we conducted ChIP assays and found that unphosphorylated STAT6 bound to a consensus STAT6 binding site located at À713 to À722 bp of the COX-2 promoter. Promoter reporter analysis showed that unphosphorylated STAT6 enhanced COX-2 promoter activities, and EMSA experiments also documented the binding of STAT6 to the COX-2 promoter sequence. Thus, unphosphorylated STAT6 may promote COX-2 transcription by directly binding to the COX-2 promoter. p300 and cyclic AMP-response element binding protein (CREB) binding protein (CBP) are transcription co-activators with close structural and functional relationships, therefore, they are generally designated p300/CBP (Shikama et al., 1997) . Here, by ChIP assay, we show that p300 binds to the same site on the COX-2 promoter as STAT6. Moreover, by co-immunoprecipitation assays, we show that p300 interacts with unphosphorylated STAT6. This finding is consistent with previous studies utilizing mammalian two-hybrid and co-immunoprecipitation assays (Gingras et al., 1999) . p300/CBP stimulate the transcription of target genes by bridging transcription factors to basal transcription machinery. In addition, they possess intrinsic histone acetyltransferase (HAT) activity (Shikama et al., 1997) . The functional roles of p300 in regulating COX-2 promoter activation have been demonstrated in previous studies of upregulation of COX-2 expression by inflammatory mediators such as phorbol 12-myristate 13-acetate, IL-1b or lipopolysaccharide (Deng et al., 2004) . In the case of STAT6, we speculate that p300 may function as a result of its HAT activity and/or by bridging active interaction between STAT6 and general transcription factors. Thus, unphosphorylated STAT6 and p300 appear to be functionally cooperating to regulate constitutive COX-2 expression.
Structurally, STAT6 is composed of N-terminal, coiled-coil, DNA binding, linker, SH2 and C-terminal transcriptional activation domains, each of which has different functions (Mikita et al., 1996) . STAT6 is 847 aa in length and the transcriptional activation domain resides in 642-847 aa. STAT6 may interact with other transcription factors including p300 through this domain (Gingras et al., 1999; McDonald and Reich, 1999) . Because the STAT6 DN form lacks the 662-847 aa, it is therefore devoid of the major portion of the transcriptional activation domain, and hence acts negatively. The STAT6 DN may compete with wild-type STAT6 to bind to the COX-2 promoter, which leads to decreased COX-2 expression.
The STAT6-dependent promotion of apoptosis resistance is consistent with recent studies. For example, cells derived from human atherosclerotic lesions are more resistant to apoptosis compared to adjacent normal cells. Microarray profiling identified STAT6 as one of the proteins whose expression was increased in apoptosis-resistant cells (Gagarin et al., 2005) . STAT6-null phenotype lymphocytes derived from imflammatory bowel disease patients show increased apoptosis (Galka et al., 2004) . In addition, knockdown of STAT6 by short hairpin RNAs results in apoptosis of human colon cancer HT-29 cells (Zhang et al., 2005) . Because elevated COX-2 has been implicated in enhancing apoptosis resistance (Sheng et al., 1998; Krysan et al., 2004) , unphosphorylated STAT6-mediated apoptosis resistance in NSCLC could be due in part to its direct regulation of COX-2 expression, though other unidentified targets of unphosphorylated STAT6 may also be involved. These results also suggest a direct role for Unphosphorylated STAT6 increases COX-2 in NSCLC X Cui et al unphosphorylated STAT6 in tumorigenesis. Previous investigations have linked constitutive phosphorylated STATs to cancer progression, however, our study, together with other recent reports indicate that attention should now be expanded to encompass unphosphorylated STATs (Kumar et al., 1997; Chatterjee-Kishore et al., 2000; Yang et al., 2005) . In summary, our study in human NSCLC cells demonstrates that unphosphorylated STAT6 contributes to constitutive COX-2 transcription via binding to the COX-2 promoter in association with transcription coactivator p300. The fact that STAT6 could be directly involved in COX-2 expression independent of the phosphorylation status sheds new light on the importance of STAT6 in cancer.
Materials and methods

Cell lines and cell culture
The cell line H2122 (adenocarcinoma) was obtained from American Type Culture Collection (Rockville, MD, USA). The A427 cell line (adenocarcinoma) was obtained from Dr JA Radosevich (Northwestern University). Cells were cultured at 371C in an atmosphere of 5% CO 2 in Rosewell Park Memorial Institute (RPMI) 1640 medium (Mediatech, Herndon, VA, USA) containing 10% fetal bovine serum (FBS) (Gemini Bio-Products, Woodland, CA, USA), 100 U/ml penicillin/streptomycin and 2 mM glutamine (Invitrogen, Carlsbad, CA, USA).
Antibodies
The antibodies used in this study includes COX-2 (Cayman Chemicals, Ann Arbor, MI, USA), STAT6 for Western blot (Cell Signaling Technology, Danvers, MA, USA), for immunofluorescence (IF) (BD Pharmingen, San Diego, CA, USA), for ChIP (Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-STAT6 (Cell Signaling Technology), p300 for Western blot, (Upstate, Lake Placid, NY, USA), for ChIP (Santa Cruz Biotechnology), normal rabbit IgG (Santa Cruz Biotechnology), mouse immunoglobulin (Ig)G 1 , k Ig (BD Pharmingen), glyceraldehyde-3-phosphate dehydrogenase (Advanced ImmunoChemical, Long Beach, CA, USA), Cy3-conjugated AffiniPure Goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA, USA) and PARP (Cell Signaling Technology).
Plasmids and stable cell lines
Plasmid pCMV (cytomegalovirus)-300 is a generous gift of Dr Michael R Stallcup (University of Southern California, Los Angeles, CA, USA). pLHCX-STAT6DN and pLXCN-STAT6Y641W were constructed by polymerase chain reaction (PCR) amplification of the DNA and then inserting into the Transfection of siRNA Cells were plated in 12-well plates at 0.8 Â 10 5 cells/well (A427) or 1.8 Â 10 5 cells/well (H2122) in RPMI medium containing 10% FBS and cultured overnight. Cells were transfected with STAT6 siRNA (Silencert predesigned siRNA STAT6, ID #4501 and #4689, Ambion, Austin, TX, USA) or negative control siRNA (Silencert Negative Control #1 siRNA, Ambion) at 3.2 mg/well utilizing TransMessenger Transfection Reagent (Qiagen, Valencia, CA, USA). Cells were lysed 48 h later with modified radioimmunoprecipitation assay buffer (RIPA buffer, 50 mM Tris-HCl, pH7.4, 150 mM NaCl, 1% Nonidet P-40 (NP-40), 0.25% sodium deoxycholic acid, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulphonyl fluoride (PMSF), 1X Complete cocktail protease inhibitor (Roche, Penzberg, Germany)). The cell lysates were subjected to Western blot.
PGE 2 enzyme-linked immunosorbent assay Cells were plated in six-well plates at 2.5 Â 10 5 (A427) or 4 Â 10 5 (H2122) cells/well in RPMI 1640 medium containing 10% FBS and cultured for 24 h. Culture medium was collected, and PGE 2 levels were determined using a PGE 2 EIA kit (Cayman Chemicals). Cells were lysed with 150 ml/well of RIPA buffer. The PGE 2 concentration was corrected by the protein concentration of the cell lysates and presented as pg/mg protein.
Immunofluorescent staining H2122 cells were grown in eight-well chamber slides. Before staining, the medium was replaced with serum-free medium and cultured overnight. Cells were fixed with methanol:acetone (1:1) at À201C for 20 min and then washed three times with phosphate-buffered saline containing 3% bovine serum albumin. Cells were incubated with primary antibodies (STAT6 or mouse IgG 1 , k Ig isotype control, BD Pharmingen) for 1 h at room temperature (RT), washed three times, and then incubated with secondary antibody (Cy3-conjugated AffiniPure Goat anti-mouse IgG, Jackson ImmunoResearch) for 30 min at RT. After the incubation, cells were washed and stained with 4 0 ,6-diamidino-2-phenylindole, dihydrochloride for 10 min.
ChIP assays
ChIP assays were performed according to the protocol of ChIP-IT kit (Active Motif, Carlsbad, CA, USA 0 . The negative control primers are from the kit. Cells were grown to 70-80% confluence and fixed with 1% formaldehyde. Cells were then lysed and centrifuged to pellet the nuclei. The nuclei were resuspended in digestion buffer and digested with the enzymatic cocktail. The resulting chromatin solution was precleared with protein G beads, followed by incubation with antibodies of STAT6 or p300 or normal rabbit IgG overnight at 41C. Protein G beads was then added and incubation continued for 1.5 h at 41C. The beads were then washed and eluted. The eluted crosslinked protein-DNA complexes was reversed by adding RNase A and incubated at 651C overnight, followed by treatment with proteinase K at 421C for 2 h. The resulting DNA was purified by columns and then subjected to PCR analysis. The PCR condition was 941C for 3 min, then 30 cycles of 941C for 30 s, 521C for 45 s and 721C for 45 s, with a final extension at 721C for 2 min. The primers to the STAT6 binding site or negative control primers would yield a fragment of 246 or 174 bp, respectively. The resulting PCR products were separated by agarose gel electrophoresis.
Co-immunoprecipitation assay 293 cells cultured in 60 mm dishes were transfected with 5 mg of pCR3.1-STAT6Y641W and/or pCMV-300 using Effectene Transfection Reagent (Qiagen). Cells were lysed with 500 ml of lysis buffer (20 mM Tris pH7.5, 100 mM NaCl, 0.5% NP-40, 0.5 mM EDTA, 0.5 mM PMSF, 1 Â protease inhibitor cocktail (Germany)) 48 h after transfection. 500 mg of protein from each sample was incubated with 5 mg of anti-p300 antibody (Santa Cruz Biotechnology) for 4 h at 41C. A total of 50 ml of Protein A-agarose (Santa Cruz Biotechnology) was then added into each sample and incubation continued for 2 h at 41C. Following the incubation, the beads were washed and boiled in sample loading buffer. The supernatant was subjected to Western blot.
Transient transfection/reporter assay
The COX-2 promoter constructs (À1432 to þ 59 bp and À327 bp to þ 59 bp in a firefly luciferase reporter vector) were generous gifts of Dr Tadashi Tanabe (National Cardiovascular Research Institute, Osaka, Japan). The phRG-TK construct containing renilla luciferase was obtained from Promega (Madison, WI, USA). Cells were seeded at a density of 1.8 Â 10 5 cells/well in 24-well plates in RPMI medium containing 10% FBS and cultured for 18 h. For each well, 0.1 mg of the COX-2 promoter construct and 0.9 mg of pCR3.1-STA-T6Y641W or pCR3.1 together with 5 ng of phRG-TK were transfected with the Effectene Transfection Reagent (Qiagen). Cells were cultured for additional 24 h before harvest. Luciferase activities were measured using the Dual-Luciferase Reporter Assay kit (Promega) following the manufacturer's instructions. Promoter activities were expressed as relative luciferase units calculated as the ratio of firefly luciferase to renilla luciferase.
EMSA assay
Nuclear extracts were prepared from H2122 cells using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Rockford, IL, USA). DNA oligo from the COX-2 promoter containing the STAT6 binding site was used as a probe. They are sense 5 0 CAGTATTTCTTCT GTTGAAAGCAACTTAGC 3 0 and antisense 5 0 GCTAA GTTGCTTTCAACAGAAGAAATACTG 3 0 . Sense strand was labeled with biotin at 5 0 end. These complementary strands were annealed before usage. The EMSA assay was performed using LightShift Chemiluminescent EMSA Kit (Pierce Biotechnology). In brief, 20 ml of binding reactions were assembled with 1 Â binding buffer, 1 mg/ml poly (dI:dC), 3 ml nuclear extract and 50 fmol biotin-target DNA. The reaction was incubated at RT for 30 min and fractionated in 5% non-denaturing polyacrylamide gel, followed by electrophoretic transfer to nylon membrane. The membrane was UV crosslinked and incubated with streptavidin-horseradish peroxidase conjugate. After the incubation, the membrane was washed and then detected by chemiluminescent method. In competition experiments, unlabeled target DNA or mutant DNA were added before biotin-labeled target DNA. The mutant probe is sense 5 0 CAGTATCGTGCTGTGCACGAGCAACTTAGC 3 0 and antisense 5 0 GTCATAGCACGACACGTGCTCGTT GAATCG 3 0 .
